Abstract: Abstract: Objective To investigate the expression of the ubiquitin-conjugating enzyme E2C (UB2C) gene in ovarian cancer by deeply excavating the gene information in the Oncomine database, and the mechanism thereof. Methods Information on the UBE2C study was collected from the Oncomine database, and changes in the level of ovarian cancer were analyzed. The relationship between UBE2C expression level and survival rate of ovarian cancer patients was analyzed by Kaplan-Meier method to explore its clinical significance. Genecards database was used to collect proteins related to the UBE2C gene, and drawing the UBE2C related protein network map through STRING. Then, the related proteins were enriched and the physiological process of protein enrichment was analyzed. Results A total of 14 research data collected in the Oncomine database on the differential expression of the UBE2C gene in ovarian cancer and normal samples were analyzed. It was found that the expression of the UBE2C gene in ovarian cancer tissue was significantly higher than that of normal ovarian tissue (P＜0.05). Kaplan-Meier survival analysis showed that the disease-free survival and total survival were significantly shorter in patients with high expression of UBE2C gene than those in patients with low expression of UBE2C gene, and the prognosis of patients with low expression of UBE2C gene was better (P＜0.05). Through the Genecards database, 25 proteins related to UBE2C were collected including RLIM, CBX4 and SIAH2. The results of the related protein enrichment showed that the main enrichment was ubiquitin-dependent protein catabolic process, protein catabolic process, protein ubiquitination, the regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, the regulation of mitotic cell cycle and cell cycle. Conclusion UBE2C gene may play a role in the occurrence and development of ovarian cancer by regulating the process of ubiquitination of protein. The high expression of UBE2C gene may be an indicator of poor prognosis in ovarian cancer patients. Targeting UBE2C may be a potential tool for the diagnosis and treatment of tumor.

Key words: ovarian neoplasms, ubiquitin-conjugating enzymes, computational biology, UBE2C gene, Oncomine datasets